Validating Intermittent Fasting for T2D, with Felicia Steger, PhD, RD
Steger discussed findings from a 6-month lifestyle investigating TRE+ER and IER.
Related Articles
Personalized Diabetes Prevention: Insights from 15 Years of the VA MOVE! Program, with Qiaochu Xue, PhD, MPH
Xue discussed her research developing a personalized prediction algorithm for predicting responders to a DPP-style intervention.
ADA 2025: CagriSema Demonstrates Dual Benefit in Obesity and Type 2 Diabetes
CagriSema shows weight loss results in recent trials comparable to existing interventions.
Universal Semaglutide Access Could Save 28 Million Lives in 5 Years, Study Finds
A global study reveals that universal access to semaglutide could save 28 million lives and significantly reduce obesity and diabetes worldwide.
QWINT-1: Weekly Insulin Efsitora Matches Daily Insulin in Type 2 Diabetes
A new study reveals once-weekly efsitora alfa effectively lowers blood glucose in type 2 diabetes, simplifying insulin therapy and enhancing patient adherence.
Diabetes Dialogue: Updates from Dexcom at ADA 2025, with Kevin Sayer
Kevin Sayer joins the program to discuss the latest from Dexcom and preview where the business is headed in an evolving diabetes landscape.
Once-Weekly Insulin Efsitora a Practical Option for Type 2 Diabetes, with Athena Philis-Tsimikas, MD
Philis-Tsimikas shared the latest findings demonstrating inferiority after switching from daily basal insulin to weekly insulin efsitora.
Diabetes Dialogue: REDFINE 1 and REDEFINE 2, with Timothy Garvey, MD, and Melanie Davies, MD
Explore groundbreaking findings from the REDEFINE trials on CagriSema’s impact on weight loss and diabetes management at ADA 2025.
Amycretin Data at ADA Highlight Efficacy, Safety of Dual-Agonist Obesity Therapy
New research reveals amycretin’s promising potential for weight loss in obesity treatment, advancing to phase 3 trials for effective management options.
Diabetes Dialogue: REDFINE 1 and REDEFINE 2, with Timothy Garvey, MD, and Melanie Davies, MD
Explore groundbreaking findings from the REDEFINE trials on CagriSema’s impact on weight loss and diabetes management at ADA 2025.
SLIMMER: Ecnoglutide Demosntrates Weight Loss Potential in Phase 3 Trial
A phase 3 trial reveals ecnoglutide significantly reduces body weight in overweight patients, showcasing its potential as a novel obesity treatment.